News
Folate Supplementation Shows Promising Results for Women with PCOS
18 April 2025
An interesting clinical trial brings encouraging news for women with polycystic ovary syndrome (PCOS), suggesting that folate supplementation may significantly improve key markers of inflammation and oxidative stress.
Quatrefolic®, the active form of folate, can reduce the damage caused by oxidation.
Conducted as a randomized, double-blind, placebo-controlled trial, the study involved 69 women aged 18 to 40 with diagnosed PCOS. Participants were divided into three groups and received either 1 mg/day folate, 5 mg/day folate, or a placebo for 8 weeks.
Researchers measured a variety of health indicators, including homocysteine levels, inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP), and oxidative stress biomarkers like total antioxidant capacity (TAC) and glutathione (GSH).
The findings were compelling. Women who received the higher folate dose experienced significant reductions in plasma homocysteine, hs-CRP, and a marker of oxidative damage (malondialdehyde). Additionally, this group saw a notable improvement in their antioxidant status.
Can Quatrefolic® normalize the homocysteine level?
One trial demonstrated that 400 mcg of Quatrefolic® (plus B6 and B12) lowered Hcy serum levels better than conventional high-dose folic acid supplementation (5 mg/day).
Tested on hypertensive subjects at low cardiovascular risk (104 patients with HCys ≥15 µmol/L), the result shows significant HCys reduction compared to baseline from 21.5 µmol/L to 10.0 µmol/L.
Moreover, the ideal HCys level was reached in 55.8% of cases in the Quatrefolic® group, and it was substantially higher than in the control.
In conclusion, these studies suggest that folate, such as Quatrefolic®, may play a valuable role in reducing inflammation and oxidative stress among women with PCOS—factors that are often linked to complications such as insulin resistance and cardiovascular risk.
